Drug, device, and nutrition conglomerate Abbott Labs (ABT)
continues to oscillate just above and below the point where it looks
like an interesting buy in the healthcare space. Valuation may not be
too demanding, investors nevertheless have reason to pause before
jumping into this name. On both sides of the soon-to-be-split business,
there is real work that needs doing.
Read more here:
While Not Expensive, Both Halves Of Abbott Need Work
No comments:
Post a Comment